On January 8, 2025 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, reported a collaboration with Genialis, the RNA-biomarker company (Press release, Tempus, JAN 8, 2025, View Source [SID1234649527]). The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Clinical care for cancer patients is hindered by insufficient biomarkers that fail to accurately predict patient response to treatment. To address this, Genialis has developed an AI foundation model using data from ~1 million RNA-sequencing samples representing globally diverse patients. This large molecular model (LMM), dubbed the Genialis TM Supermodel, yields accurate and information-rich biomarker algorithms to help biopharma improve therapeutic development. Validating Genialis’ LMM using Tempus real-world multi-modal data is essential to demonstrate the clinical utility and broad applicability of these biomarkers in drug development and clinical practice. As part of the collaboration, Genialis can now leverage Tempus’ analytics platform, Lens, which provides a development platform accessing de-identified multimodal patient records and a suite of tools to validate signatures to accelerate the company’s efforts to bring its clinical algorithms to market. In return, Tempus gains the right to evaluate and potentially license Genialis-developed algorithms for commercialization as a component of the xR platform.
Tempus multimodal dataset has already proved pivotal in the launch of GenialiskrasID, the first commercially available algorithm that stratifies patients who benefit from KRAS inhibition. Presented at the 6th Annual Targeting-RAS Drug Development Summit in September 2024, Genialis krasID uniquely predicts patient response to KRAS-targeted therapies across cancer types and driver mutations. Independently validated using Tempus’ real-world data, Genialis krasID stratifies patients into high and low likelihood response groups that have been evaluated in real-world studies1,2.
"We look forward to working with Genialis and demonstrating new ways in which our data can be applied to further a new kind of research, one that embraces the power that RNA-based biomarkers can have on the future of cancer care," said Kate Sasser, Ph.D., Chief Scientific Officer at Tempus. "Multimodal algorithms, including RNA signatures, are demonstrating rapid advancement in clinical utility for personalized treatment decisions, and we are excited to partner with Genialis to fuel this data-driven precision medicine future with our xR assay and vast multimodal dataset."
"Biomarkers have the potential to transform how cancer is diagnosed and treated, but today’s standard of care leaves a lot to be desired in terms of accuracy, information richness, and patient reach," said Rafael Rosengarten, Ph.D., CEO of Genialis. "With this strategic agreement with Tempus, Genialis will have access to an unparalleled data resource to validate our cutting-edge patient classifiers."